UNSPSC 51373410: Ammonium/bromodiphenhydramine/codeine/diphenhydramine/potassium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373410 Ammonium/bromodiphenhydramine/codeine/diphenhydramine/potassium is a Commodity code covering pharmaceutical products — specifically branded and generic pharmaceutical formulations — that state and local governments procure for public health, emergency response, and institutional care. Recent activity shows purchases of naloxone formulations and multi-source generic pharmaceuticals supplied through authorized wholesalers to county health departments, state agencies, and participating public facilities. Issuing bodies include county health departments, state procurement offices, and cooperative purchasing alliances serving state and local members. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, have posted recent solicitations under or aligned with this code tier.

Geographic activity spans Florida and the Upper Midwest, with MMCAP extending coverage across multiple states including Oregon. Seminole County posted an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the procurement is potentially FEMA-funded and requires E-Verify compliance, drug-free workplace certification, and commercial general liability insurance. MMCAP issued an RFP (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, sourced through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), with awards effective July 1, 2026; evaluation weightings emphasize price competitiveness (75 percent) and vendors must certify cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with at least two of the three wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence.